Focal Segmental Glomerulosclerosis Drugs Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Focal Segmental Glomerulosclerosis Drugs Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for focal segmental glomerulosclerosis drugs has experienced significant expansion over recent years. From a valuation of $17 billion in 2025, it is projected to climb to $18.58 billion by 2026, reflecting a compound annual growth rate of 9.3%. This upward trajectory in the historical period has been driven by several factors, including the scarcity of available treatments, a high incidence of kidney disorders, a heavy dependence on corticosteroid therapies, growing awareness surrounding FSGS, and progress made in the development of immunosuppressive medications.
The market for focal segmental glomerulosclerosis drugs is projected to expand rapidly over the coming years. By 2030, it is anticipated to reach $27.71 billion, driven by a compound annual growth rate (CAGR) of 10.5%. This forecasted growth is fueled by advances in biologics and monoclonal antibodies, the growing adoption of personalized medicine, increased funding for rare disease research, the integration of technology into treatment development, and improved healthcare infrastructure in emerging markets. Key trends shaping this period include the evolution of personalized medicine, ongoing research into targeted therapeutics, a broadening pipeline for rare disease drugs, more efficient clinical trial designs, and innovations in immunomodulatory therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Focal Segmental Glomerulosclerosis Drugs Market Demand Drivers Creating New Revenue Opportunities
The growth of the focal segmental glomerulosclerosis (FSGS) drugs market is expected to be driven by increasing healthcare expenditure. Healthcare expenditure is defined as the total funds allocated to healthcare services, related goods, and activities within a specific system or economy over a given timeframe. Higher healthcare spending can support the development and accessibility of FSGS drugs by boosting research funding and clinical trials, thereby enhancing drug production. For example, in November 2023, the Canadian Institute for Health Information reported that Canada’s total health spending is projected to reach $344 billion in 2023, or $8,740 per person. This represents a 2.8% rise from the previous year, compared to a 1.5% increase in 2022, signaling a significant recovery in healthcare investment. Consequently, rising healthcare expenditures are fueling the expansion of the FSGS drugs market.
Focal Segmental Glomerulosclerosis Drugs Market Segment Analysis Highlighting Growth Areas
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Focal Segmental Glomerulosclerosis Drugs Market Trends Driving Strategic Industry Expansion
Major players in the focal segmental glomerulosclerosis (FSGS) market are intensifying their emphasis on product innovation and development to deliver dependable solutions to their clientele and reinforce their competitive standing. A notable example occurred in February 2023, when Travere Therapeutics, a biopharmaceutical firm based in the United States, introduced FILSPARI for focal segmental glomerulosclerosis (FSGS), following its approval by the Food and Drug Administration (FDA), a federal agency in the U.S. This oral medication is intended for the treatment of IgA nephropathy (IgAN). It represents the initial and sole non-immunosuppressive therapy designed to reduce proteinuria in IgAN, a rare kidney condition. Moreover, FILSPARI has received orphan drug designation from authorities in both the United States and Europe for the management of IgAN and focal segmental glomerulosclerosis (FSGS).
Focal Segmental Glomerulosclerosis Drugs Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio, Alexion Pharmaceuticals, Bayer AG, Novartis AG, Pfizer Inc., Johnson and Johnson Ltd., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Fresenius Kabi Ltd., Gilead Sciences Inc, Reata Pharmaceuticals, Amgen Inc
Access The Complete Focal Segmental Glomerulosclerosis Drugs Market Report:
Focal Segmental Glomerulosclerosis Drugs Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2025. The regions covered in the focal segmental glomerulosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
